Oral Vaccination Against <i>Helicobacter pylori</i> with Recombinant Cholera Toxin B‐Subunit

Kubota, Eiji; Joh, Takashi; Tanida, Satoshi; Sasaki, Makoto; Kataoka, Hiromi; Watanabe, Kentaro; Itoh, K.; Oshima, Tadayuki; Ogasawara, Nagahisa; Togawa, Shouzo; Wada, Takeshi; Yamada, Tomonori; Mori, Yoshinori; Fujita, Fumitaka; Shimura, Takaya; Ohara, Hirotaka; Isaka, Masanori; Yasuda, Yoko; Itoh, Makoto

doi:10.1111/j.1523-5378.2005.00328.x

Cited by 11 publications

(9 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The efficacy of DNA vaccination in mice was confirmed [52]. Inactive recombinant cholera toxin B subunit and nontoxic mutant of cholera toxins were shown effective in mice [55,56]. It was successfully expressed in tobacco and in probiotic bacteria, where it conferred protection after oral administration in mice [53,54].…”

Section: Vaccine Development and Probioticsmentioning

confidence: 94%

See 1 more Smart Citation

Inflammation, Immunity, Vaccines for Helicobacter Infection

Chmiela

Michetti

2006

Helicobacter

View full text Add to dashboard Cite

The reason why some individuals remain Helicobacter pylori infected for life but without any symptoms while others develop severe diseases is only partially clarified. Presumably, it depends on multifactorial interactions among host immunologic and physiologic factors, bacterial virulence determinants, and environmental influences modulating the host response. Much effort has been made to identify host genetic factors that may explain an individual susceptibility of the host to H. pylori infection. The identification of H. pylori determinants and the elucidation of their role in modifying the host immune responses were further delineated. The ability of H. pylori to overcome the defense mechanisms on mucosal surfaces as well as to modulate the immune response by interfering with host recognition and transduction systems has been shown. Also new bacterial anti-inflammatory defense systems have been described. Findings in experimental animal models and humans with natural H. pylori infection suggested a double role of regulatory T cells in the course of H. pylori infection: protecting the infected host against excessive gastric inflammation and, in contrast, promoting bacterial colonization.

show abstract

Section: Vaccine Development and Probioticsmentioning

confidence: 94%

“…It was successfully expressed in tobacco and in probiotic bacteria, where it conferred protection after oral administration in mice [53,54]. Inactive recombinant cholera toxin B subunit and nontoxic mutant of cholera toxins were shown effective in mice [55,56].…”

Section: Vaccine Development and Probioticsmentioning

confidence: 99%

Inflammation, Immunity, Vaccines for Helicobacter Infection

Chmiela

Michetti

2006

Helicobacter

View full text Add to dashboard Cite

show abstract

“…intranasally and orally. When giving H. pylori antigens together with recombinant cholera B subunit, Kubota et al (2005) induced slightly higher antibody responses in the stomach but comparable immune responses in the intestine after oral as compared to after intranasal immunization of mice. We could show that for therapeutic immunization with H. pylori lysate, oral administration was considerably more effective and gave rise to stronger mucosal CD4+ and IgA antibody responses than intraperitoneal injection (Nystrom et al , 2006).…”

Section: Administration Of Candidate H Pylori Vaccines/antigensmentioning

confidence: 95%

Progress in vaccine development againstHelicobacter pylori

Svennerholm

Lundgren

2007

FEMS Immunol Med Microbiol

View full text Add to dashboard Cite

Based on the very high prevalence of diseases caused by Helicobacter pylori, particularly in the developing world, and the rapid emergence of antibiotic resistance among clinical isolates, there is a strong rationale for an effective vaccine against H. pylori. In this review we describe recent promising candidate vaccines and prophylactic or therapeutic immunization strategies for use against H. pylori, as well as studies to identify immune responses that are related to protection in experimental animals. We also describe identification of different types of immune responses that may be related to protection against symptoms based on comparisons of H. pylori-infected patients with duodenal ulcers or gastric cancer and asymptomatic carriers. We conclude that there is still a strong need to clarify the main protective immune mechanisms against H. pylori as well as to identify a cocktail of strong protective antigens, or recombinant bacterial strains that express such antigens, that could be administered by a regimen that gives rise to effective immune responses in humans.

show abstract

“…This is present in the oral cholera vaccine Dukoral™, providing a history of safe oral use in humans. Immune responses and protection in cholera models have been demonstrated with recombinantly produced CTB [68,69], and strong responses to other antigens are generated when co-administered with recombinant CTB [70,71], confirming that the effect is due to the presence of CTB alone, and not the presence of low levels of cholera toxin A fragment (CTA).…”

Section: Encapsulation Vehiclesmentioning

confidence: 99%

Formulation technologies for oral vaccines

New

2019

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Summary Many options now exist for constructing oral vaccines which, in experimental systems, have shown themselves to be able to generate highly effective immunity against infectious diseases. Their suitability for implementation in clinical practice, however, for prevention of outbreaks, particularly in low‐ and middle‐income countries (LMIC), is not always guaranteed, because of factors such as cost, logistics and cultural and environmental conditions. This brief overview provides a summary of the various approaches which can be adopted, and evaluates them from a pharmaceutical point, taking into account potential regulatory issues, expense, manufacturing complexity, etc., all of which can determine whether a vaccine approach will be successful in the late stages of development. Attention is also drawn to problems arising from inadequate diet, which impacts upon success in stimulating effective immunity, and identifies the use of lipid‐based carriers as a way to counteract the problem of nutritional deficiencies in vaccination campaigns.

show abstract

Oral Vaccination Against Helicobacter pylori with Recombinant Cholera Toxin B‐Subunit

Abstract: The present study indicated that rCTB has systemic and mucosal immunoadjuvanticities against H. pylori and that oral vaccination with rCTB might additively support antibiotic eradication.

Cited by 11 publications

References 23 publications

Inflammation, Immunity, Vaccines for Helicobacter Infection

Inflammation, Immunity, Vaccines for Helicobacter Infection

Progress in vaccine development againstHelicobacter pylori

Formulation technologies for oral vaccines

Contact Info

Product

Resources

About